Viral Vector Purified for Gene Therapy and Vaccine Development

Recombinant AAV is a class of viral vectors used for gene therapy and vaccination purposes.

Recombinant AAV is a preferred class of viral vectors used for gene therapy and vaccination purposes. Recently, improved recombinant AAV vectors have gained rapid popularity in gene therapy because of their lack of pathogenicity, wide range of infectivity, and ability to establish long-term transgene expression.

Purifying the virus after propagation in host cells is a critical step towards using it as a vector for genetic modification of target cells. Fast-Trap virus purification and concentration kits contain all components needed for the entire virus purification workflow.

Fast-Trap kits, produced by Millipore Corp. (Billerica, MA, USA), are also available for adenovirus and lentivirus. All Fast-Trap kits contain the reagents and devices necessary to purify virus from cellular contaminants and the expressed recombinant transgene. The kits yield concentrated virus in the exchange buffer of choice.

"Traditional methods for purifying AAV, such as cesium chloride ultracentrifugation, are labor-intensive and time-consuming,” said Ken Ludwig, group product manager for cell biology at Millipore. "These methods result in viral vector preparations that have variable quality and, as a result, lower infection effectiveness. The new Fast-Trap AAV methodology allows for complete purification of high quality, recombinant AAV in less than 10 minutes.”

Related Links:
Millipore